Novavax is set to release its quarterly earnings on May 9, 2025, with analysts expecting earnings per share of $0.19 and projected revenue of $204.1 million.
The company’s recent multi-billion-dollar agreement with Sanofi highlights a significant shift in its revenue strategy, focusing on partnerships over direct product sales.
Financial metrics indicate challenges, including a negative P/E ratio of -5.09 and a debt-to-equity ratio of -0.37, but also potential undervaluation with an enterprise value to sales ratio of 0.97.
Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company specializing in vaccine development, leveraging a unique technology platform that includes protein-based nanoparticles and the Matrix-M® adjuvant. Known for its COVID-19 vaccine, Novavax is actively expanding its pipeline to include other infectious diseases, competing with vaccine developers like Moderna and Pfizer.
On May 9, 2025, NVAX will release its quarterly earnings before the market opens. Analysts expect earnings per share to be $0.19, with projected revenue of $204.1 million. The Zacks Consensus Estimate aligns with these figures, predicting $71.84 million in sales and 19 cents per share in earnings. In the previous quarter, Novavax exceeded earnings estimates by 32%, raising expectations for this report.
Novavax’s recent multi-billion-dollar agreement with Sanofi is a significant development. Sanofi has acquired exclusive rights to market Novavax’s COVID-19 vaccine globally, except in certain regions. This deal means Novavax won’t record product sales from its COVID-19 vaccine in the upcoming earnings report. Investors will focus on updates regarding Novavax’s pipeline during the earnings call.
The company’s financial metrics reveal challenges. Novavax has a negative P/E ratio of -5.09, indicating negative earnings. The price-to-sales ratio is 1.41, suggesting investors pay $1.41 for every dollar of sales. The enterprise value to sales ratio is 0.97, which may indicate undervaluation. However, the enterprise value to operating cash flow ratio is -7.61, reflecting negative cash flow.
Novavax’s debt-to-equity ratio is -0.37, showing more liabilities than equity. The current ratio is 0.98, indicating nearly enough current assets to cover liabilities. Despite these challenges, Novavax’s growth strategy involves forming new partnerships and investing in its early-stage pipeline, focusing on infectious diseases and potential expansion into other areas.
